000 03181nam a22005295i 4500
001 978-3-642-28160-0
003 DE-He213
005 20140220083311.0
007 cr nn 008mamaa
008 120420s2012 gw | s |||| 0|eng d
020 _a9783642281600
_9978-3-642-28160-0
024 7 _a10.1007/978-3-642-28160-0
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
100 1 _aIgnatiadis, Michail.
_eeditor.
245 1 0 _aMinimal Residual Disease and Circulating Tumor Cells in Breast Cancer
_h[electronic resource] /
_cedited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2012.
300 _aXIV, 253p. 35 illus., 28 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aRecent Results in Cancer Research,
_x0080-0015 ;
_v195
520 _aMost deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.   In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:   -  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis? -  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits? -  How are DTCs and CTCs relevant to clinical research and practice? - What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids? -  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?   This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aGynecology.
650 0 _aCancer
_xSurgery.
650 0 _aPathology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aGynecology.
650 2 4 _aSurgical Oncology.
650 2 4 _aPathology.
650 2 4 _aCancer Research.
700 1 _aSotiriou, Christos.
_eeditor.
700 1 _aPantel, Klaus.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642281594
830 0 _aRecent Results in Cancer Research,
_x0080-0015 ;
_v195
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-28160-0
912 _aZDB-2-SME
999 _c102743
_d102743